Omeros Corporation (OMER) AI Stock Analysis

Omeros Corporation is a biopharmaceutical firm that discovers, develops, and commercializes small-molecule and protein-based therapeutics. The company targets orphan indications and diseases linked to inflammation, complement-mediated disorders, cancers involving dysfunctional immune systems, and addictive disorders. Its lead candidate, Narsoplimab, has completed pivotal studies for HSCT-TMA and is in Phase III trials for IgAN and aHUS, alongside Phase II trials for COVID-19. Other pipeline programs include OMS405 in Phase II for opioid and nicotine addiction, OMS527 in Phase I for addiction and movement disorders, and OMS906 in Phase I for paroxysmal nocturnal hemoglobinuria, supplemented by preclinical research across multiple inhibitor platforms.

Over the reported annual periods, revenue fluctuated significantly, moving from $64.8M in FY2017 down to $29.9M in FY2018, before rising to $111.8M in FY2019 and ending at $90.5M in FY2021. Annual net losses expanded from -$53.5M in FY2017 to -$111.4M in FY2021, driven partly by annual R&D expenses reaching $118.8M. For the trailing twelve months ended June 30, 2026, revenue stood at $38.4M, with an operating margin of 0.3% and a profit margin of 324.9%. In the latest quarter, quarterly revenue growth was 14.9% year-over-year.

As of June 30, 2026, Omeros held $132.0M in cash and short-term investments alongside total debt of $83.8M, resulting in net cash of $48.2M. Total assets were $286.8M, and the current ratio was 1.95. However, the company reported negative shareholders' equity of -$51.3M. In FY2025, capital expenditures were minimal at $65,000. In historical annual results, cash burn was substantial, with free cash flow of -$110.0M in FY2021. Over a 5-year period, share count grew by 43.3%.

OMER trades at a market capitalization of $1.17B and an enterprise value of $1.53B. The stock's trailing P/E is 13.3x, below the 24.6x median of its US-listed Healthcare peers, but its forward P/E of 87.7x sits well above the peer median of 17.3x. Additionally, its price-to-sales of 30.5x and EV/EBITDA of 163.7x trade at large premiums to the peer medians of 4.1x and 12.0x, respectively. Over the past year, the stock returned 64.8%, outperforming the S&P 500 (SPY) return of 16.8%.

Consensus coverage includes 2 Strong Buy ratings and 1 Hold rating, with no Sell or Strong Sell ratings. The mean price target is $27.50, representing a 69.8% premium to the last close of $16.20. For the fiscal year ending December 31, 2026, analysts estimate revenue of $127.5M and EPS of $0.69. For the next fiscal year, 2 analysts project revenue of $221.3M and EPS of $1.23. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Omeros Corporation (OMER). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OMER income statement, OMER balance sheet, OMER key metrics, OMER analyst forecast, OMER chart. See the OMER stock overview for the latest quote and news.